{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:00:18Z","timestamp":1792202418486,"version":"4.4.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Primary nuclear protein in testis (NUT) carcinoma is a rare malignant tumor originating from the salivary glands that usually occurs in midline structures, such as the head and neck, and has been identified in young patients. Progression of NUT carcinoma is rapid, and there is a high degree of malignant invasion. The median survival time of NUT carcinoma patients is 6 to 9 months, and 80% of the patients die within 1 year after diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case description<\/jats:title>\n                    <jats:p>This case report summarizes the treatment of a 36-year-old male patient with NUT carcinoma of the right parotid gland. The overall survival of the patient was 2 years. We also discuss the applications and outcomes of immune checkpoint inhibitor and targeted therapy combination regimens in the treatment of NUT carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We suggest that targeted therapy combined with immunotherapy which has long-term clinical benefits and targeted therapy which has high clinical response rate(immunotherapy + dual-targeting three-drug regimens) is an ideal choice for the treatment of patients with rare and\/or refractory tumors and will not compromise patient safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>identifier ChiCTR1900026300.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2023.1094770","type":"journal-article","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T01:02:07Z","timestamp":1682989327000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["The whole treatment process and thinking of a patient with NUT carcinoma of the parotid gland: a case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Shujuan","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunya","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixian","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199124000-00011","article-title":"Intrathoracic carcinoma in an 11-year-old girl showing a translocation t(15;19)","volume":"13","author":"Kees","year":"1991","journal-title":"Am J Pediatr hematology\/oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210852","article-title":"BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells","volume":"27","author":"French","year":"2008","journal-title":"Oncogene"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1702086114","article-title":"Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma","volume":"114","author":"Alekseyenko","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-18-0474","article-title":"\"Z4\" complex member fusions in NUT carcinoma: implications for a novel oncogenic mechanism","volume":"16","author":"Shiota","year":"2018","journal-title":"Mol Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0014","article-title":"NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism","volume":"4","author":"French","year":"2014","journal-title":"Cancer Discovery"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s12105-013-0428-1","article-title":"The importance of diagnosing NUT midline carcinoma","volume":"7","author":"French","year":"2013","journal-title":"Head Neck Pathol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s12105-020-01254-9","article-title":"NUT carcinoma arising from the parotid gland: a case report and review of the literature","volume":"15","author":"Saik","year":"2021","journal-title":"Head Neck Pathol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3969\/j.issn.1005-4979.2021.03.014","article-title":"Nuclear protein of the testis carcinoma of the parotid gland: a case report","volume":"31","author":"Jinyun","year":"2021","journal-title":"J Oral Maxillofac Surg"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/hed.26067","article-title":"Prevalence of NUT carcinoma in head and neck: analysis of 362 cases with literature review","volume":"42","author":"Lee","year":"2020","journal-title":"Head Neck"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.02.107","article-title":"Midline carcinoma of children and young adults with NUT rearrangement","volume":"22","author":"French","year":"2004","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1153","article-title":"Clinicopathologic features and long-term outcomes of NUT midline carcinoma","volume":"18","author":"Bauer","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-018-4882-y","article-title":"Patterns of care and impact of prognostic factors in the outcome of NUT midline carcinoma: a systematic review and individual patient data analysis of 119 cases","volume":"275","author":"Giridhar","year":"2018","journal-title":"Eur Arch oto-rhino-laryngol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12105-017-0858-2","article-title":"NUT midline carcinoma: a series of five cases, including one with unusual clinical course","volume":"12","author":"Kakkar","year":"2018","journal-title":"Head Neck Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s12105-016-0763-0","article-title":"NUT midline carcinoma of the nasal cavity","volume":"11","author":"Edgar","year":"2017","journal-title":"Head Neck Pathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s12105-017-0809-y","article-title":"NUT midline carcinoma of the sublingual gland: clinical presentation and review","volume":"11","author":"Seim","year":"2017","journal-title":"Head Neck Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001046","article-title":"NUT carcinoma of the salivary glands: clinicopathologic and molecular analysis of 3 cases and a survey of NUT expression in salivary gland carcinomas","volume":"42","author":"Agaimy","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/s41467-020-15290-0","article-title":"Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction","volume":"11","author":"Yin","year":"2020","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1200\/JCO.2020.38.15_suppl.4519","article-title":"A phase ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC)","volume":"38","author":"Zhu","year":"2020","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"New Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10456-017-9552-y","article-title":"Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy","volume":"20","author":"Ramjiawan","year":"2017","journal-title":"Angiogenesis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31921","article-title":"Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in HCC","volume":"74","author":"Yi","year":"2021","journal-title":"Hepatology"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1094770\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T01:02:16Z","timestamp":1682989336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1094770\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,2]]},"references-count":22,"alternative-id":["10.3389\/fonc.2023.1094770"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1094770","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,2]]},"article-number":"1094770"}}